在患有左心室辅助装置的患者中进行结构性心脏干预
Puvi Seshiah1, Eugene Chung1, Santiago Garcia1
1The Christ Hospital Heath Network, The Heart & Vascular Institute, Cincinnati, OH 45219, USA.
Reviews in cardiovascular medicine
|May 12, 2025
概括
左心室辅助器件 (LVAD) 改善了晚期心力衰竭患者的治疗结果. 本综述详细介绍了使用量身定制的透导管干预措施在LVAD患者中诊断和治疗结构性心脏病.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 干预心脏病学 干预心脏病学
背景情况:
- 左心室辅助器件 (LVAD) 显著改善了晚期心力衰竭 (HF) 患者的生存率和生活质量.
- 患有LVAD的患者经常出现复杂的并发症和结构性心脏病,需要专门的护理.
- 本土心脏的功能对LVAD支持至关重要,使其结构完整性至关重要.
研究的目的:
- 提供对LVAD患者结构性心脏病的诊断和治疗的全面审查.
- 强调HF心脏病专家,外科医生和干预专家之间的多学科合作的重要性.
- 突出针对LVAD相关并发症的个性化过导管干预策略.
主要方法:
- 关于LVAD患者结构性心脏病的当前文献和临床实践的审查.
- 讨论用于识别LVAD电路和本源心力衰竭的诊断方式.
- 对特定结构性损伤的跨导管干预技术的分析.
主要成果:
- 在LVAD电路和本地心脏中存在多个故障点,包括反性膜病变,心房间间的分流和流出管阻塞.
- 过导管干预为这些复杂的结构性心脏问题提供量身定制的解决方案.
- 成功的管理需要一个协作,个性化的方法.
结论:
- 结构性心脏病对LVAD患者构成重大风险,影响发病率和死亡率.
- 早期诊断和及时,量身定制的跨导管干预是改善结果的关键.
- 多学科的合作对于优化这种复杂的患者群体的护理至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Heart Failure Drugs: Inotropic Agents
426
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
426


